Table 2.

Clinical outcomes of patients who underwent EUS-radiofrequency ablation combined with systemic chemotherapy

Characteristics	Number of patients, n(%)
Number of RFA sessions, median (IQR)	5 (3.25-5.75)
Time interval from diagnosis to EUS-RFA (months), median (IQR)	4.73 (2.66-9.65)
Follow-up period (months), median (IQR)	21.23 (10.73-27.1)
Treatment failure	20 (95.5)
Local progression	13 (59.1)
Distant metastasis	7 (31.8)
Both	1 (4.5)
Adverse events	4/107 (3.74)
Abdominal pain	3
Peritonitis	1

IQR: Interquartile range; EUS-RFA: EUS-radiofrequency ablation